CinCor Pharma, Inc.
Net BuyingCINC·US·🇺🇸 US
63%buys·37%sales
246 transactions$730.8MTotal buys·77 buys
$430KTotal sells·45 sells
4040 insiders
Last: Feb 24, 2023
| Date | Insider | Type | Value | |
|---|---|---|---|---|
| Feb 24, 23 | de Garidel Marc | Disposition | - | |
| Feb 24, 23 | de Garidel Marc | Disposition | - | |
| Feb 24, 23 | THERO JOHN F | Disposition | - | |
| Feb 24, 23 | THERO JOHN F | Disposition | - | |
| Feb 24, 23 | Pearce Catherine | Disposition | - | |
| Feb 24, 23 | Pearce Catherine | Disposition | - | |
| Feb 24, 23 | Lee June | Disposition | - | |
| Feb 24, 23 | Kalb Michael Wayne | Disposition | - | |
| Feb 24, 23 | Ignelzi Troy A. | Disposition | - | |
| Feb 24, 23 | Ignelzi Troy A. | Disposition | - |
CinCor Pharma, Inc. (CINC) has recorded 246 insider transactions from 40 insiders. Total insider buying volume stands at $730.8M, while total selling volume is $430K. Overall insider sentiment is bullish (63% purchases).
CinCor Pharma, Inc. (CINC) has recorded 246 insider operations, including 77 open-market purchases ($730.8M), 45 sales ($430K) and 124 other operations (stock option exercises, grants, tax dispositions, donations). The insider sentiment is bullish (63% purchases).
CinCor Pharma, Inc. shows moderate insider activity with 7 active months out of the last 12, typical of a company whose trading windows are concentrated around financial disclosures.
Among the most active insiders are de Garidel Marc (CEO), Kalb Michael Wayne (CFO) & Coelho Mary Theresa (CFO), with respectively 6, 194, 33 transactions.
Across all 246 recorded transactions, the breakdown by type is: exercise (85, 35%), buys (77, 31%), sales (45, 18%), disposition (27, 11%), grant (11, 4%).
Data sourced from regulatory filings (SEC Form 4, AMF, BaFin, FI, and other European authorities).
CinCor Pharma, Inc. has recorded 246 insider operations in total, including 77 open-market purchases ($730.8M), 45 sales ($430K) and 124 other operations (stock option exercises, grants, tax dispositions, donations). The most recent transaction was recorded on February 24, 2023.
Insiders at CinCor Pharma, Inc. are currently net buyers, with 63% purchases and 37% sales across all reported transactions. Total buy volume is $730.8M versus $430K in sales, indicating a bullish insider sentiment.
InsiderLens tracks 40 insiders at CinCor Pharma, Inc. (CINC). de Garidel Marc (CEO, 6 tx), Kalb Michael Wayne (CFO, 194 tx), Coelho Mary Theresa (CFO, 33 tx). Data is sourced from mandatory regulatory filings for persons with access to privileged information.
The insider signal for CINC is bullish, based on a 63% buy ratio across 122 buy and sell transactions reported to financial regulators. Transactions from C-suite executives (CEO, CFO) and board members are generally considered the most informative signals.
Insider trading data for CinCor Pharma, Inc. comes from official regulatory filings: SEC Form 4 (United States), AMF (France), BaFin (Germany), FI (Sweden), and other European financial authorities. These filings are mandatory for directors, officers, and holders of more than 10% of a company's shares. InsiderLens aggregates and normalizes this data for analysis.